Allotera Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
45
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$150M
- Investors
-
14
Allotera Therapeutics General Information
Description
Developer of allogeneic CAR-T cell therapies designed to treat hematological cancers. The company offers off-the-shelf CAR-T cell therapies, gene-editing technology, and advanced cell manufacturing capabilities, enabling healthcare providers and patients with hematological malignancies to access targeted cell therapies with improved availability and treatment potential.
Contact Information
Website
www.alloteratx.comCorporate Office
- 4260 Forest Park Avenue
- Suite 100
- Saint Louis, MO 63108
- United States
Corporate Office
- 4260 Forest Park Avenue
- Suite 100
- Saint Louis, MO 63108
- United States
Allotera Therapeutics Timeline
Allotera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 08-Jul-2026 | $150M | Completed | Clinical Trials - Phase 2 | ||
| 2. Early Stage VC (Series B) | 16-Dec-2022 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC (Series A) | 13-Apr-2020 | $36M | $36M | Completed | Clinical Trials - Phase 2 |
Allotera Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B | 20,938,376 | $0.000010 | $0.62 | $7.75 | $7.75 | 1x | $7.75 | 12.89% |
| Series A | 11,673,206 | $0.000010 | $0.28 | $3.56 | $3.56 | 1x | $3.56 | 7.19% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Allotera Therapeutics Patents
Allotera Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026107398-A2 | Improved methods of making genome-edited immune effector cells | Pending | 15-Nov-2024 | ||
| WO-2026107398-A3 | Improved methods of making genome-edited immune effector cells | Pending | 15-Nov-2024 | ||
| US-20240189355-A1 | Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use | Pending | 14-Nov-2022 | ||
| WO-2024107742-A1 | Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use | Inactive | 14-Nov-2022 | ||
| AU-2023371649-A1 | Generation of cd3 expressing immune cells for use in conjunction with cd3 binding bispecific targeting agents | Pending | 04-Nov-2022 | A61K40/15 |
Allotera Therapeutics Signals
Allotera Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Therapy Acceleration Program (TAP) | Not-For-Profit Venture Capital | Minority | ||
| Abingworth | Venture Capital | Minority | ||
| Aisling Capital | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Alpha Wave Global | Growth/Expansion | Minority |
Allotera Therapeutics FAQs
-
When was Allotera Therapeutics founded?
Allotera Therapeutics was founded in 2018.
-
Where is Allotera Therapeutics headquartered?
Allotera Therapeutics is headquartered in Saint Louis, MO.
-
What is the size of Allotera Therapeutics?
Allotera Therapeutics has 45 total employees.
-
What industry is Allotera Therapeutics in?
Allotera Therapeutics’s primary industry is Drug Discovery.
-
Is Allotera Therapeutics a private or public company?
Allotera Therapeutics is a Private company.
-
What is the current valuation of Allotera Therapeutics?
The current valuation of Allotera Therapeutics is .
-
What is Allotera Therapeutics’s current revenue?
The current revenue for Allotera Therapeutics is .
-
How much funding has Allotera Therapeutics raised over time?
Allotera Therapeutics has raised $358M.
-
Who are Allotera Therapeutics’s investors?
Therapy Acceleration Program (TAP), Abingworth, Aisling Capital, Alexandria Venture Investments, and Alpha Wave Global are 5 of 14 investors who have invested in Allotera Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process